Optimising Outcomes in the Management of Hyperuricaemia and Gout

Optimising Outcomes in the Management of Hyperuricaemia and Gout

A badge with ribbon in color black Cat3B: 1 non-core pt | An analog clock in color black 2h | A black calendar with white triangle in center that has a black exclamation point in the middle 25 Nov 2020 

Overview

About this course

Long-standing and uncontrolled hyperuricaemia often leads to gouty arthropathy. This chronic inflammatory condition has not only been linked to debilitating disease, a low quality of life and shortened life expectancy, but is also associated with comorbid diseases such as cardiovascular and renal disease. Treating to target is important in preventing flares and avoiding these preventable complications. In this course, data on the clinical presentation of gout and the recent science on hyperuricaemia and urate lowering treatment options will be discussed by a global expert.


Learning outcomes

  1. To understand the pathophysiology of gouty arthropathy
  2. To review the clinical presentation of gout
  3. To recognise the non-gouty complications (e.g. cardiovascular and renal disease) associated with hyperuricaemia and gout
  4. To understand the concept of treating to target
  5. To enumerate international recommendations on the diagnosis and management of hyperuricaemia and gout

Topics covered

  1. The pathophysiology, clinical presentation and impact of hyperuricaemia and gout
  2. Symptomatic therapy, preventive therapy and urate lowering therapy (ULT)
  3. Unmet needs in conventional gout therapy
  4. The concept of treating to target
  5. Efficacy and safety data of febuxostat in gout

1 Non-core CME Point Available (Cat 3B)

  • Score at least 80% in the multiple-choice quiz.
  • A certificate can be downloaded upon successful completion. Please attach the certificate when claiming your points in the SMC website.

Sponsored by

AST_Logo_RGB_resized.jpg